Therapy and Pharmacokinetics
1985; Wiley; Volume: 39; Issue: 3 Linguagem: Inglês
10.1111/j.1440-1819.1985.tb02017.x
ISSN1440-1819
Tópico(s)Non-Invasive Vital Sign Monitoring
ResumoPsychiatry and Clinical NeurosciencesVolume 39, Issue 3 p. 401-414 Therapy and Pharmacokinetics First published: September 1985 https://doi.org/10.1111/j.1440-1819.1985.tb02017.xAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1 Bruni, J., Wilder, B.J., Bauman, A.W. and Willmore, L.J.: Clinical efficacy and long-term effects of valproic acid therapy on spike-and-wave discharges. Neurology 30: 42–46, 1980. 10.1212/WNL.30.1.42 PubMedWeb of Science®Google Scholar 2 Henriksen, O. and Johannessen, S.I.: Clinical pharmacokinetic observations on sodium valproate—A 5-year follow-up study in 100 children with epilepsy. Acta Neurol Scandinav 65: 504–523, 1982. 10.1111/j.1600-0404.1982.tb03106.x PubMedWeb of Science®Google Scholar 3 Maheshwari, M.C. and Jeavons, P.M.: The effect of sodium valproate (Epilim) on the EEG. Electroencephalogr Clin Neurophysiol 39: 429, 1975. CASPubMedGoogle Scholar 4 Villarreal, H.J., Wilder, B.J., Willmore, L.J., et al.: Effect of valproic acid on spike and wave discharges in patients with absence seizures. Neurology 28: 886–891, 1978. 10.1212/WNL.28.9.886 PubMedWeb of Science®Google Scholar 5 Bernhard, C.G., Bohm, E. and Höjeberg, S.: A new treatment of status epilepticus, intravenous injections of a local anesthetic (lidocaine). Arch Neurol Psychiatry 74: 208–214, 1955. 10.1001/archneurpsyc.1955.02330140092017 CASPubMedWeb of Science®Google Scholar 6 Bohm, E., Flodmark, S. and Petersén, I.: Effect of lidocaine (Xylocaine) on seizure and interseizure electroencephalograms in epileptics. Arch Neurol Psychiatry 81: 550–556, 1959. 10.1001/archneurpsyc.1959.02340170016002 CASPubMedWeb of Science®Google Scholar 7 Collinsworth, K.A., Kalman, S.M. and Harrison, D.C.: The clinical pharmacology of lidocaine as an antiarrhythmic drug. Circulation 50: 1217–1230, 1974. 10.1161/01.CIR.50.6.1217 CASPubMedWeb of Science®Google Scholar 8 Grossman, J.I., Lubow, L.A., Frieden, J. and Rubin, I.L.: Lidocaine in cardiac arrhythmias. Arch Intern Med 121: 396–401, 1968. 10.1001/archinte.1968.03640050006002 CASPubMedWeb of Science®Google Scholar 9 Julian, R.M.: Lidocaine in experimental epilepsy: correlation of anticonvulsant effect with blood concentrations. Electroencephalogr Clin Neurophysiol 34: 639–645, 1973. 10.1016/0013-4694(73)90009-6 PubMedWeb of Science®Google Scholar 10 Koch-Weser, J.: Antiarrhythmic prophylactic in ambulatory patients with coronary heart disease. Arch Intern Med 129: 763–772, 1972. 10.1001/archinte.129.5.763 CASPubMedWeb of Science®Google Scholar 11 LeLorier, J., Grenon, D., Latour, Y. et al.: Pharmacokinetics of lidocaine after prolonged intravenous infusions in uncomplicated myocardial infarctions. Ann Intern Med 87: 700–702, 1977. 10.7326/0003-4819-87-6-700 CASPubMedWeb of Science®Google Scholar 12 Lemmen, L.J., Klassen, M. and Duiser, B.: Intravenous lidocaine in the treatment of convulsions. JAMA 239: 2025, 1978. 10.1001/jama.239.19.2025 PubMedWeb of Science®Google Scholar 13 Ochs, H.R., Knüchel, M. and Abernethy, D.R. et al.: Dose-independent pharmacokinetics of intravenous lidocaine in humans. J Clin Pharmacol 23: 186–188, 1983. 10.1002/j.1552-4604.1983.tb02723.x CASPubMedWeb of Science®Google Scholar 14 Thompson, P. D., Melmon, K.L. and Richardson, J.A. et al.: Lidocaine pharmacokinetics in advanced heart failure, liver disease and renal failure in humans. Ann Intern Med 78: 499–508, 1973. 10.7326/0003-4819-78-4-499 PubMedWeb of Science®Google Scholar 15 Browne, T.R.: Clonazepam; a review of a new anticonvulsant drug. Arch Neurol 33: 326–332, 1976. 10.1001/archneur.1976.00500050012003 CASPubMedWeb of Science®Google Scholar 16 Browne, T.R.: Clonazepam. In: J. Koch-Weser, (Ed.), Drug therapy. N Engl J Med 299: 812–816, 1978. 10.1056/NEJM197810122991505 PubMedWeb of Science®Google Scholar 17 Levy, R.H. and Pitlick, W.H.: Carbamazepine, interactions with other drugs. In: D.M. Woodbury, J.K. Penry and C.E. Pippenger (Ed.). Antiepileptic drugs, 2nd Ed. Raven Press, New York , pp. 497–506, 1982. Web of Science®Google Scholar 18 Simonsen, N., Olsen, P.Z., Kuhl, V., Lund, M. and Wendelboe, J.: A comparative controlled study between carbamazepine and diphenylhydantoin in psychomoter epilepsy. Epilepsia 17: 169–176, 1976. 10.1111/j.1528-1157.1976.tb03394.x PubMedWeb of Science®Google Scholar 19 Carraz, G., Gau, R., Chateau, R. et al.: Communication a propos des premiers essais clinics sur l'activité antiépileptique de l'acide N-dipropylacétique (sel de Na+). Ann Med Psychol 122: 577–585, 1964. CASPubMedGoogle Scholar 20 Chapman, A., Keane, P.E., Meldrum, B.S. et al.: Mechanism of anticonvulsant action of valproate. Progress Neurobiol 19: 315–359, 1982. 10.1016/0301-0082(82)90010-7 CASPubMedWeb of Science®Google Scholar 21 Pinder, R.M., Brogden, R.N., Speight, T.M. et al.: Sodium valproate: A review of its pharmacological properties and therapeutic efficacy in epilepsy. Drugs 13: 81–123, 1977. 10.2165/00003495-197713020-00001 CASPubMedWeb of Science®Google Scholar 22 Van Der Kleijn, E., Guelen, F., Schobben, F. et al.: Clinical pharmacokinetics of antiepileptic drugs. In: M.J. Parsonage and A.D.S. Caldwell, (Ed.), The place of sodium valproate in the treatment of epilepsy. Roy Soc Med Int Cong Symp 30: 73–91, 1980. Google Scholar 23 Kurata, K., Kido, H., Ito, T., Kobayashi, K., Yamaguchi, N., Matsubara, R., Ichimura, F., Yokogawa, K. and Yamana, T.: Rapid saturation method of phenytoin in the treatment of status epileptics: A pharmacokinetic study. J Jpn Epil Soc 2: 58–66, 1984. Google Scholar 24 Martin, C.H.: Comparability of different products of the same drug in man. Drug Information Bull 3: 72–74, 1969. Google Scholar 25 Stewart, M.J., Ballinger, B.R., Delvin, E.J., Miller, A.Y. and Ramsey, A.C.: Bioavailability of phenytoin. A comparison of two preparations. Euro J Clin Pharmacol 9: 209–212, 1975. 10.1007/BF00614019 CASPubMedWeb of Science®Google Scholar 26 Bittencourt, P.R.M., Fresty, V.A. and Richens, A.: Quantitative assessment of smooth-pursuit eye movement in healthy and epileptic subjects. J Neurol Neurosurg and Psychiat 43: 1119–1124, 1980. 10.1136/jnnp.43.12.1119 PubMedWeb of Science®Google Scholar 27 Holzman, P.S., Proctor, L.R., Levy, D.L., Yasillo, N.J., Meltzer, H.Y. and Hurt, S.W.: Eye-tracking dysfunctions in schizophrenic patients and their relatives. Psychiatry 31: 143–151, 1974. CASPubMedWeb of Science®Google Scholar 28 Matsue, Y., Wagatsuma, S., Ito, K. and Okuma: Smooth-pursuit eye movements in epileptics under antiepileptic medication. Tohoku J Exp Med 134: 341–349, 1981. 10.1620/tjem.134.341 CASPubMedWeb of Science®Google Scholar Volume39, Issue3September 1985Pages 401-414 ReferencesRelatedInformation
Referência(s)